Table 2 Summary of clinical response from baseline to week 24
Clinical response | Intention to treat population | |
Chemotherapy group (n = 87) | Endocrine therapy group (n = 87) | |
MRI+ | ||
  CR | 14 (16.3%) | 2 (2.3%) |
  PR | 58 (67.4%) | 43 (50.6%) |
  CR + PR | 72 (83.7) | 45 (52.9%) |
Calliper* | ||
  CR | 27 (31%) | 17 (19.5%) |
  PR | 46 (52.9%) | 45 (51.5%) |
  CR + PR | 73 (83.9%) | 62 (71.3%) |
Pathologic response | Chemotherapy group (n = 87) | Endocrine therapy group (n = 83) |
 pCR | 3 (3.4%) | 1 (1.2%) |
 pCR (breast) | 5 (5.7%) | 1 (1.2%) |
 pCR (axillary lymph node) | 12 (13.8%) | 4 (4.9%) |